Misonix Announces the Second Largest U.S. Commercial Payer Has Provided Coverage for TheraSkin® to Treat All Lower Extremity Dermal Wounds Adding 32 Million New Covered Lives

FARMINGDALE, N.Y., Dec. 18, 2020 (GLOBE NEWSWIRE) — 2020) – Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that the second largest U.S. Commercial payer will now cover TheraSkin for all lower extremity dermal wounds. TheraSkin is a proven cellular and tissue-based treatment for difficult to heal chronic wounds.

“This favorable decision by the second largest commercial payer in the U.S. to provide broad coverage of TheraSkin for the treatment of all lower extremity wounds, including venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs), is a strong testament to the versatility, clinical effectiveness and safety of Theraskin, and the weight of the clinical evidence supporting TheraSkin’s results,” stated Stavros Vizirgianakis, Misonix Chief Executive Officer. “Since our acquisition of Solsys Medical in 2019, Misonix has made significant progress in positioning Theraskin as an accepted standard of care treatment for patients suffering from difficult to heal chronic wounds and has received overwhelming positive feedback from health practitioners across the country regarding their clinical experience and positive patient outcomes. With this new coverage, we now have an additional 32 million covered lives we can address with Theraskin, and we expect this number to grow as we continue to work with private payers to expand TheraSkin coverage.”

TheraSkin is an all human split thickness allograft with living cells, growth factors, and a native extracellular matrix. TheraSkin vascularizes to build granulation tissue and accelerates epithelialization to close wounds.^1,2,3 Clinical studies demonstrate significant benefits from treatment of chronic lower extremity dermal wounds with TheraSkin, including improvements in healing time and healing rates.^1,2,3 TheraSkin has been applied to over 100,000 wounds.

1. Flood MS, et al. Treatment of Deep Full-Thickness Wounds Containing Exposed Muscle, Tendon, and/or Bone using a Bioactive HumanSkin Allogrfat: A large Cohort Case Series.
2. Barbul A, et al. Matched-cohort study comparing bioactive human split-thickness skin allograft plus standard of care to standard of care alone in the treatment of diabetic ulcers: A retrospective analysis across 470 institutions. Wound Repair Regen. 2020 Jan; 28(1): 81-89
3. Gurtner GC, et al. A retrospective matched-cohort study of 3994 lower extremity wounds of multiple etiologies across 644 institutions comparing a bioactive human skin allograft, TheraSkin, plus standard of care, to standard of care alone. Int Wound J. 2020 Feb; 17(1): 55-64

About Misonix, Inc.
Misonix, Inc. (Nasdaq: MSON) is a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. Its surgical team markets and sells BoneScalpel and SonaStar, which facilitate precise bone sculpting and removal of soft and hard tumors and tissue, primarily in the areas of neurosurgery, orthopedic, plastic and maxillo-facial surgery. The Company’s wound team markets and sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service. At Misonix, Better Matters! That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve outcomes for patients. Additional information is available on the Company’s web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, access to capital, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking statements.